The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma

類似資料

• Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
  著者:: Desjardins, Annick, 等
  出版事項: (2008)
• AT-22 PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION
  著者:: Ghiaseddin, Ashley, 等
  出版事項: (2014)
• Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
  著者:: Reardon, David A., 等
  出版事項: (2011)
• Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
  著者:: Reardon, David A., 等
  出版事項: (2011)
• Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
  著者:: Peters, Katherine B., 等
  出版事項: (2015)